17 research outputs found
Results from the multivariable regression model evaluating the association between the inverse of carotid Intima Media Thickening (c-IMT) and various explanatory factors.
<p>CI = Confidence Interval. The final sample included 196 patients.</p
Kaplan-Meier estimates of time to vascular events by alexithymia (TAS-20 score ≥50 versus TAS-20 score <50).
<p>Kaplan-Meier estimates of time to vascular events by alexithymia (TAS-20 score ≥50 versus TAS-20 score <50).</p
Results from the Cox proportional hazards regression analyses predicting time to vascular events.
<p>Results from the Cox proportional hazards regression analyses predicting time to vascular events.</p
Clinical, behavioral and socio-demographic characteristics of the final sample (n = 201).
<p>Clinical, behavioral and socio-demographic characteristics of the final sample (n = 201).</p
Characteristics of the sample according to the presence of atherosclerotic plaque (IMT<sub>max</sub> ≥1.5 mm).
*<p>Kruskal-Wallis test for continuous variables; chi-squared test for categorical ones.</p>**<p>59 missing values (21 among those with plaque; 38 among other participants).</p
Table_1_Development and validation of a prediction score for failure to casirivimab/imdevimab in hospitalized patients with COVID-19 pneumonia.DOCX
IntroductionCasirivimab and imdevimab (CAS/IMV) are two non-competing, high-affinity human IgG1 anti-SARS-CoV-2 monoclonal antibodies, that showed a survival benefit in seronegative hospitalized patients with COVID-19. This study aimed to estimate the day-28 risk of mechanical ventilation (MV) and death in individuals hospitalized for severe COVID-19 pneumonia and receiving CAS/IMV. Additionally, it aimed to identify variables measured at the time of hospital admission that could predict these outcomes and derive a prediction algorithm.MethodsThis is a retrospective, observational cohort study conducted in 12 hospitals in Italy. Adult patients who were consecutively hospitalized from November 2021 to February 2022 receiving CAS/IMV were included. A multivariable logistic regression model was used to identify predictors of MV or death by day 28 from treatment initiation, and β-coefficients from the model were used to develop a risk score that was derived by means of leave-one-out internal cross-validation (CV), external CV, and calibration. Secondary outcome was mortality.ResultsA total of 480 hospitalized patients in the training set and 157 patients in the test set were included. By day 28, 36 participants (8%) underwent MV and 28 died (6%) for a total of 58 participants (12%) experiencing the composite primary endpoint. In multivariable analysis, four factors [age, PaO2/FiO2 ratio, lactate dehydrogenase (LDH), and platelets] were independently associated with the risk of MV/death and were used to generate the proposed risk score. The accuracy of the score in the area under the curve (AUC) was 0.80 and 0.77 in internal validation and test for the composite endpoint and 0.87 and 0.86 for death, respectively. The model also appeared to be well calibrated with the raw data.ConclusionThe mortality risk reported in our study was lower than that previously reported. Although CAS/IMV is no longer used, our score might help in identifying which patients are not likely to benefit from monoclonal antibodies and may require alternative interventions.</p
T-cells activation and proliferation in Immunological Non Responders with and without HAART intensification with MVC.
<div><p><b>A</b>-<b>B</b>. T-cell activation defined as the co-expression of HLA-DR and CD38 on CD4+ and CD8+.</p>
<p><b>C</b>-<b>D</b>. T-cell proliferation defined as the expression of Ki67 on CD4+ and CD8+.</p>
<p>The vertical lines represent median and interquartile ranges (25<sup>th</sup> and 75<sup>th</sup> percentiles).</p></div
Flow chart illustrating the entire study population.
<p>Flow chart illustrating the entire study population.</p
Univariate and multivariate predictors of event (eGFR decline > 5%) in the study population (144 patients).
<p>Univariate and multivariate predictors of event (eGFR decline > 5%) in the study population (144 patients).</p